Anti-Human CD27/TNFRSF7 Reference Antibody (Boserolimab, RUO)
- Catalog number: BS11481
- Availability: In Stock
$326.00
- Ex Tax: $326.00
Description: Boserolimab (BS11481) is a research-grade recombinant antibody targeting CD27L. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD27Lreceptor,TNFRSF7,T14,CD27antigen,Tumornecrosisfactorreceptorsuperfamilymember7,CD27,T-cellactivationantigenCD27
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: MK-5890,anti-cd27agonist
Background: CD27 antigen is a ~29 kDa protein. Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells. The CD70-CD27 signaling pathway mediates antigen-specific T-cell activation and expansion which in turn provides immune surveillance of B-cells. Mechanistically, CD70 ligation activates the TRAF2-PTPN6 axis that subsequently inhibits LCK phosphorylation to promote phenotypic and transcriptional adaptations of T-cell memory. In addition, activation by CD70 on early progenitor cells provides a negative feedback signal to leukocyte differentiation during immune activation and thus modulates hematopoiesis. Negatively regulates the function of Th2 lymphocytes in the adipose tissue.
References:
1. Izawa, K. et al. (2017) The Journal of experimental medicine 214, 73-89. PMID: 28011863
2. Jaeger-Ruckstuhl, CA. et al. (2024) Immunity 57, 287-302.e12. PMID: 38354704
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Human
Isotype: IgG1
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD27Lreceptor,TNFRSF7,T14,CD27antigen,Tumornecrosisfactorreceptorsuperfamilymember7,CD27,T-cellactivationantigenCD27
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: MK-5890,anti-cd27agonist
Background: CD27 antigen is a ~29 kDa protein. Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells. The CD70-CD27 signaling pathway mediates antigen-specific T-cell activation and expansion which in turn provides immune surveillance of B-cells. Mechanistically, CD70 ligation activates the TRAF2-PTPN6 axis that subsequently inhibits LCK phosphorylation to promote phenotypic and transcriptional adaptations of T-cell memory. In addition, activation by CD70 on early progenitor cells provides a negative feedback signal to leukocyte differentiation during immune activation and thus modulates hematopoiesis. Negatively regulates the function of Th2 lymphocytes in the adipose tissue.
References:
1. Izawa, K. et al. (2017) The Journal of experimental medicine 214, 73-89. PMID: 28011863
2. Jaeger-Ruckstuhl, CA. et al. (2024) Immunity 57, 287-302.e12. PMID: 38354704
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
SDS-PAGESDS-PAGE for Research Grade Boserolimab.
